Skip to main content

Table 2 Data to be obtained during the PANGAEA pharmacoeconomic sub-study

From: The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice

 

Baseline

Follow up visits

Final visit (24 months)

UKNDS

X

at 12 months

X

EQ-5D, PRIMUS-A, PRIMUS-L

X

every 6 months

X

Compliance questionnaire

X

every 3 months

X

TSQM-9

X

every 3 months

X

Consumption of resources

X

every 3 months

X

  1. UKNDS: UK (Guy’s) Neurological Disability Scale; EQ-5D: Euro quality of life questionnaire, PRIMUS: Patient Reported Outcome Indices for Multiple Sclerosis (subscale A: activity, L: quality of life); TSQM-9: Treatment Satisfaction Questionnaire for Medication
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us